ANDA 207107, held by Sagent Pharmaceuticals. Esmolol Hydrochloride.
As of Nov 21, 2026, ANDA 207107 (Esmolol Hydrochloride), held by Sagent Pharmaceuticals, was first approved by FDA on Jun 8, 2018, with 1 approved supplement and 0 published complete response letters.
Esmolol Hydrochloride in Sodium Chloride Injection is a beta adrenergic blocker indicated for the short-term treatment of: Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia Control of perioperative tachycardia and hypertension 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 8, 2018 | Original application | Approved | None posted |
| Esmolol Hydrochloride1GM/100ML · injectable;injection | Esmolol Hydrochloride | Rx |
| Esmolol Hydrochloride2GM/100ML · injectable;injection | Esmolol Hydrochloride | Rx |
| Oct 22, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 8, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters